Controlled Substances Diversion & Pill Mill Defense
Former Director of DOJ’s Appalachian Regional Prescription Opioid Strike Force (ARPO). Nationwide Defense for Physicians, Pharmacists, Clinic Owners, Telehealth Executives, Hospitals, and Wholesalers in Federal Criminal and DEA Administrative Proceedings.
At DOJ, Scott Armstrong served as lead trial counsel in the Fraud Section’s first-ever use of data analytics to investigate, prosecute, and try, after a two-week trial, a physician and clinic owner for conspiring to unlawfully dispense over 2 million opioid pills.
Based in Washington, D.C., Armstrong & Bradylyons PLLC defends physicians, pharmacists, pharmacy owners, pain clinic operators, psychiatrists, nurse practitioners, hospital systems, wholesalers, and telehealth executives in federal controlled substances matters nationwide. The work covers criminal prosecutions, DEA registration actions, and civil Controlled Substances Act proceedings involving opioids, stimulants, benzodiazepines, muscle relaxants, sedatives, anabolic steroids, and buprenorphine.
The firm’s founding partner, Scott Armstrong, served as Director of the Appalachian Regional Prescription Opioid Strike Force (ARPO) at DOJ’s Fraud Section, the Department’s dedicated strike force for prosecuting medical professionals who illegally prescribed and distributed controlled substances. Under ARPO, DOJ charged more than 120 defendants collectively responsible for prescribing over 115 million pills across 10 federal districts in six states.
The enforcement architecture changed in 2026. On April 7, 2026, DOJ created the National Fraud Enforcement Division and moved the Healthcare Fraud Unit, which houses the Prescription Strike Force, under it. DEA reported a record 928 actions against registrants in the enforcement year ending with the June 2026 takedown. Prescribers and pharmacies are now far more likely to lose a registration or a revenue stream before they see an indictment.
The firm’s healthcare fraud defense practice brings over 25 years of combined DOJ experience. Drew Bradylyons supervised the Healthcare Fraud Unit’s Florida Strike Force and later served as Chief of EDVA’s Financial Crimes and Public Corruption Unit, overseeing parallel criminal, civil, and administrative proceedings involving more than $1 billion in claims. The firm’s attorneys tried 17 federal jury trials in healthcare fraud cases at DOJ involving over $2.8 billion in alleged false claims.
The government tries these cases. DOJ’s Healthcare Fraud Unit completed nine jury trials through early June 2026, securing convictions in all of them, after 17 trials in 2025. A defense built on the assumption that the case will resolve short of a jury is a defense built on a bad assumption.
Scott Armstrong led the prosecutors and data analysts at ARPO who identified targets and built prescribing cases, and he tried those cases as lead trial counsel.
He also served as lead trial counsel in the Fraud Section’s first prescribing case built on data analytics, a two-week jury trial of a physician and clinic owner charged with conspiring to unlawfully dispense over 2 million opioid pills. The analytical method the government now runs against prescribers nationwide was developed in cases like that one.
Diversion cases run on a fixed set of inputs: DEA ARCOS data, state monitoring records, pharmacy dispensing data, undercover encounters, cooperating patients and staff, financial tracing, and Medicare Part D claims. Those inputs do not change when the drug changes. The tools that produced opioid prosecutions now produce stimulant and benzodiazepine prosecutions.
Trial preparation drives the result at every earlier stage. The firm retains clinical and pharmacology experts before the government’s theory hardens, tests the prescribing data before its summary charts are finalized, and develops impeachment on cooperating witnesses before they are locked into testimony. Drew Bradylyons adds supervisory experience with the parallel proceedings that define a 2026 diversion case.
The 2026 National Health Care Fraud Takedown
On June 23, 2026, DOJ announced the 2026 National Health Care Fraud Takedown: 455 defendants charged across 56 federal districts in schemes involving more than $6.5 billion in alleged false claims. Thirty-six of them, including 28 licensed medical professionals, were charged with diverting opioids and other controlled substances. In the Eastern District of Pennsylvania, three defendants were charged over a voicemail refill line that issued Schedule II refills without clinician contact and kept operating after patients who used it died of overdoses.
DEA’s Record Year Against Registrants
The larger numbers were administrative. DEA Administrator Terrance Cole announced that, since October 1, 2025, the agency had issued a record 928 actions against registrants: 205 Orders to Show Cause, 53 Immediate Suspension Orders, and 642 surrenders for cause. Surrenders outnumbered contested actions by more than two to one. More than six hundred registrants signed away prescribing authority without a hearing and without anyone testing the agency’s evidence.
Trials and Sentences in 2026
In August 2026, a Texas physician was sentenced to 12.5 years for a Kingwood clinic that issued prescriptions for more than 3 million opioid pills, with cash pricing keyed to street value and staff payments to move dealers’ patients to the front of the line. The government charged the full chain: a nurse practitioner received 96 months, the pharmacist who filled the prescriptions 42 months, the clinic’s security guard 63 months, and a dealer who supplied patients 210 months. In May 2026, a jury in the Southern District of Texas convicted another physician of distributing more than a million pills, on evidence of near-universal opioid and carisoprodol combination prescribing in the strongest short-acting formulations.
Stimulants, Telehealth, and the Done Global Sentences
On July 7, 2026, the founder and former CEO of Done Global was sentenced to six years and fined $1 million, with the clinical president receiving two years and the same fine, in a scheme involving more than 37 million pills of Adderall and other stimulants. The proof targeted platform design rather than individual prescriptions: capped visit windows, compensation tied to prescribing, auto-refills issued without clinical interaction, and direction to clinicians to disregard DSM-5 criteria. This was DOJ’s first criminal drug distribution prosecution of a digital health company, and it is now the template for platform cases.
Civil Penalties and the Coming Telemedicine Rule
Registrants that never face charges still face civil penalties under 21 U.S.C. § 842, usually paired with a multi-year memorandum of agreement. In July 2026, a university health system paid $4.17 million and signed a three-year agreement with DEA over unreported thefts and losses and recordkeeping failures. Prescribers relying on pandemic-era telemedicine flexibility are also on a deadline. A fourth temporary extension permits Schedule II through V prescribing without a prior in-person examination through December 31, 2026, and DEA’s special registration final rule entered White House review on August 25, 2026, with final action projected for November.
A diversion case rarely arrives on one track. A criminal investigation runs alongside a DEA registration action, a state board complaint, a payer audit, and sometimes a civil penalty demand. Statements made in any one are available in all the others.
Establishing That Prescribing Was Within the Usual Course of Professional Practice
Every prescribing case turns on whether the prescription was issued for a legitimate medical purpose by a practitioner acting in the usual course of professional practice under 21 C.F.R. § 1306.04. The firm retains pain management specialists, psychiatrists, addiction medicine physicians, and pharmacology experts to explain the clinical record to a jury. In Ruan v. United States, 597 U.S. 450 (2022), the Supreme Court held that the government must prove the practitioner subjectively knew or intended that the prescribing was unauthorized. Deviation from a standard of care is not the offense.
Challenging the Government’s Pattern and Outlier Evidence
Prosecutors build these cases on ARCOS reporting, state monitoring data, pharmacy dispensing records, and Medicare Part D claims. The government selects a peer group, identifies the prescriber as an outlier on volume, drug mix, patient geography, or combination prescribing, and reduces it to a chart. The firm retains data analysts to test the peer group, the time frame, the exclusions, and the arithmetic, and to supply the clinical explanations the model does not capture, including specialty, referral base, and patient acuity.
Immediate Suspension Orders, Orders to Show Cause, and Corrective Action Plans
An Immediate Suspension Order under 21 U.S.C. § 824(d) stops all controlled substance activity the day it is served, before any hearing. An Order to Show Cause leaves the registration active but starts a 30-day clock to answer, and unanswered allegations are deemed admitted. A registrant served with an Order to Show Cause may submit a corrective action plan under § 824(c); a registrant served with an ISO may not. The firm has defended a nurse practitioner against an Order to Show Cause and a physician assistant against an Immediate Suspension Order, both arising from prescribing at a leading national testosterone clinic, and filed an application for a temporary restraining order against DEA challenging that suspension.
Attacking Proof of Knowledge, Cooperators, and Undercover Encounters
The government proves intent through cooperating patients, former staff, and recorded undercover visits. Cooperating patients have their own exposure and their own agreements. Former employees describe what they observed, not what the prescriber knew. An undercover encounter captures a single visit, answered with the history taken, the examination performed, and the documentation created. The firm builds the good-faith record from contemporaneous charts, treatment plans, and monitoring practices.
Sequencing Criminal, Administrative, Licensing, and Civil Exposure
A DEA hearing, a state board proceeding, and a civil penalty negotiation each generate sworn statements and document productions that criminal prosecutors can use. Answering an Order to Show Cause on the merits while a grand jury is sitting requires coordination, not improvisation. The firm evaluates criminal exposure before any administrative submission is filed and manages Fifth Amendment, privilege, and timing questions across every forum at once.
Ryan Haight Compliance and the Coming Special Registration Rule
The Ryan Haight Act, 21 U.S.C. § 829(e), generally requires an in-person evaluation before a controlled substance is prescribed online, subject to exceptions and the temporary flexibility running through December 31, 2026. The Done Global prosecution shows what the government examines in a platform case: visit length, compensation design, refill automation, discharge policy, and marketing. The firm defends telehealth companies and executives on those issues and evaluates prescribing programs against DEA’s pending special registration rule.
Federal diversion investigations reach every participant in the prescribing and dispensing chain. The 2026 cases charged physicians, nurse practitioners, pharmacists, clinic staff, platform executives, and the dealers who supplied patients, often in the same indictment.
Physicians, Psychiatrists, and Mid-Level Prescribers
Prescribers remain the primary targets under 21 U.S.C. § 841. ADHD prescribers face growing exposure where the government alleges diagnoses unsupported by DSM-5 criteria, and nurse practitioners and physician assistants at national men’s health and testosterone clinics now face DEA registration actions over remote evaluation and documentation practices. Mid-level providers are charged directly, not treated as peripheral: a nurse practitioner in the Kingwood pill mill case received 96 months. The defense is built on the clinical record, the examinations performed, and the practitioner’s actual knowledge.
Pharmacists and Pharmacy Owners
Pharmacists carry a corresponding responsibility under 21 C.F.R. § 1306.04 to confirm that a prescription was issued for a legitimate medical purpose. The government charges those who dispensed despite red flags: volume from a single prescriber, cash payment, long-distance patients, early refills, and opioid plus benzodiazepine plus muscle relaxant combinations. Pharmacies also face Immediate Suspension Orders that halt dispensing the day they are served. The firm defends the criminal case and the registration together, and documents the verification the pharmacist actually performed.
Pain Clinic and Pill Mill Operators
The government applies the pill mill label to clinics it alleges functioned as distribution operations: high volume, cash pricing, minimal examination, and prescribers who signed without individualized evaluation. Owners face distribution, conspiracy, maintaining a drug-involved premises, healthcare fraud, and money laundering counts together. The defense establishes legitimate clinical operations and contests the inference that business decisions equal distribution intent.
Telehealth Companies and Platform Executives
The Done Global sentences confirmed that founders, chief executives, and clinical leadership face prison for platform design that drives prescribing. The government examines visit-length caps, compensation tied to prescription volume, automated refills, restrictions on discharging patients, and marketing aimed at people seeking a specific medication. The firm defends telehealth executives and medical directors by documenting clinical oversight and credentialing and by separating aggressive growth from criminal distribution.
Hospitals, Health Systems, and Institutional Registrants
Hospitals, surgery centers, long-term care facilities, and clinics hold DEA registrations and carry independent obligations to secure controlled substances, maintain accurate inventories, and report thefts and significant losses. DEA Diversion Investigators pursue these failures through civil penalties under 21 U.S.C. § 842 and multi-year memoranda of agreement. The firm responds to Notices of Inspection, negotiates penalty resolutions, and keeps a documentation problem from becoming a diversion allegation.
Wholesalers, Distributors, and Clinic Staff
Distributors and their executives face exposure for failing to maintain effective controls against diversion and to report suspicious orders. Clinic managers, office staff, and patient recruiters face conspiracy charges under 21 U.S.C. § 846 for scheduling, collecting cash, or moving patients through a clinic. Non-clinician participants in the 2026 Texas cases received 42 to 210 months. The defense challenges proof of knowledge, willful participation, and the scope of the alleged agreement.
These investigations follow a recognizable sequence. Knowing the sequence tells a practitioner what the government already has.
ARCOS, Monitoring Programs, and Claims Data
The DEA’s Automation of Reports and Consolidated Orders System tracks controlled substances from manufacturer through distribution, and state monitoring programs record every dispensed prescription. Investigators use both to flag prescribers and pharmacies that stand apart from their peers on volume, drug mix, patient distance, formulation strength, and combination prescribing. Medicare Part D and Medicaid claims add the payment layer, and the Health Care Fraud Data Fusion Center converts the flags into referrals. Outlier status is the entry point for most investigations.
The Registration Action as an Investigative Step
DEA frequently acts on the registration before prosecutors act on the case. A field visit, a Notice of Inspection, or an Order to Show Cause usually means investigators have already assembled a record the registrant has not seen. The 642 surrenders for cause reported for the year ending June 2026 show how often that first encounter ends the matter.
Undercover Operations
DEA sends undercover agents to obtain prescriptions, presenting fabricated pain, ADHD symptoms, or anxiety depending on the drug at issue. The encounter is recorded, and the resulting prescription becomes the government’s cleanest exhibit. The defense examines the full visit rather than the clip: the history taken, the examination performed, the records reviewed, and whether the agent volunteered facts a reasonable clinician would credit.
Patient and Staff Cooperators
Agents interview current and former patients and employees for testimony that patients did not need the medication, sold it, paid cash, or were never examined. Every cooperator arrives with exposure, an agreement, and an incentive to describe the prescriber’s intent rather than their own observations. That gap between what a witness observed and what the witness claims the prescriber knew is where cross-examination works.
Financial Tracing
Investigators analyze bank records, cash deposits, payment applications, and subscription revenue for income inconsistent with legitimate practice. Cash pricing tied to street value, structured deposits, and luxury purchases are treated as distribution proceeds. In platform cases, advertising spend establishes scale.
Search Warrants and Electronic Evidence
Agents execute warrants at clinics, pharmacies, and residences, and serve cloud warrants under 18 U.S.C. § 2703. In platform cases the targets are internal policies, prescriber dashboards, refill logic, and marketing materials. Internal communications about visit caps, discharge policy, or prescribing quotas carry more weight at trial than any single chart.
Diversion prosecutions combine Controlled Substances Act counts with healthcare fraud statutes. Individual prescriptions can be charged as separate counts, which is how one practice produces an indictment carrying decades of exposure.
Unlawful Distribution and Dispensing (21 U.S.C. § 841)
Section 841 is the primary charge. For prescribers it means issuing prescriptions outside the usual course of professional practice and without a legitimate medical purpose; for pharmacists, knowingly filling them. Schedule II substances, including oxycodone, hydrocodone, and amphetamines, carry up to 20 years per count, with a 20-year mandatory minimum where death or serious bodily injury results. Schedule IV substances, including most benzodiazepines, carry up to five years per count.
Conspiracy (21 U.S.C. § 846)
Section 846 carries the same penalties as the object offense and requires no overt act. It is how the government joins prescribers, pharmacists, clinic managers, platform executives, and recruiters in one indictment. A conviction does not require proof that the defendant wrote a prescription or dispensed a pill.
Maintaining a Drug-Involved Premises (21 U.S.C. § 856)
Section 856 reaches anyone who manages or controls a place and knowingly makes it available for distributing controlled substances. Prosecutors use it against clinic and pharmacy owners who were not prescribers. It carries up to 20 years.
Use of a Communication Facility (21 U.S.C. § 843)
Section 843(b) prohibits using any communication facility, including telephones, faxes, electronic prescribing systems, and telehealth platforms, to facilitate a drug offense. Each use is a separate count carrying up to four years. In platform cases the number of available counts is substantial.
Healthcare Fraud (18 U.S.C. § 1347)
Section 1347 is charged where the prescribing generated claims to Medicare, Medicaid, TRICARE, or private insurers, including visits that existed only to produce prescriptions. The maximum is 10 years per count, rising to 20 for serious bodily injury and to life where death results. Pairing fraud and distribution counts lets the government argue that evidence on one supports intent on the other, which is a point for motions in limine and limiting instructions.
Anti-Kickback Statute (42 U.S.C. § 1320a-7b)
The Anti-Kickback Statute applies where clinics pay recruiters or marketers to steer patients, or where prescriber compensation tracks referrals or prescription volume. Violations carry up to 10 years each and convert resulting claims into false claims for civil purposes.
Money Laundering and Forfeiture (18 U.S.C. §§ 1956, 1957, 982)
Money laundering counts follow the cash and the subscription revenue and carry up to 20 years. Forfeiture allegations accompany the indictment and often reach clinic accounts, real property, and vehicles before trial. The financial counts frequently carry exposure exceeding the distribution counts.
Civil Penalties Under the Controlled Substances Act (21 U.S.C. § 842)
Section 842 supports civil penalties for recordkeeping failures, failure to report thefts or significant losses, dispensing without a valid prescription, and, for manufacturers and distributors, failure to report suspicious orders. Penalties accrue per violation, so a reporting failure spanning years produces large exposure without any allegation that drugs reached the street. Resolutions typically include a memorandum of agreement imposing audits, training, and security requirements.
Registration Revocation, Exclusion, and Licensure
DEA may suspend or revoke a registration under 21 U.S.C. § 824 on grounds including a controlled substance felony conviction, loss of state authority, program exclusion, or conduct inconsistent with the public interest. A conviction for a program-related offense triggers mandatory exclusion from federal healthcare programs. State medical, pharmacy, and nursing boards proceed on their own schedules and often act on an indictment rather than a verdict.
What Did the 2026 National Health Care Fraud Takedown Mean for Prescribers and Pharmacies?
The 2026 National Health Care Fraud Takedown, announced June 23, 2026, charged 455 defendants across 56 federal districts. Thirty-six of them, including 28 licensed medical professionals, were charged with diverting prescription opioids and other controlled substances.
The criminal numbers understate the enforcement. DEA reported a record 928 administrative actions against registrants over the preceding year, and CMS announced 1,079 payment suspensions and 1,403 billing privilege revocations in connection with the same action. For most practitioners and pharmacies, the realistic risk is not an indictment. It is the loss of a registration or a revenue stream through a proceeding with no jury, no prosecutor, and a deadline measured in days.
The charged conduct shows where the government is looking: refill practices that bypass clinician contact, clinics supplied with patients by dealers, cash pricing keyed to street value, and combination prescribing. Cases involving patient deaths change both the charging posture and the sentencing exposure.
What Is a DEA Immediate Suspension Order and What Happens the Day It Is Served?
An Immediate Suspension Order suspends a DEA registration the moment it is served, before any hearing. Under 21 U.S.C. § 824(d), DEA may suspend simultaneously with instituting revocation proceedings on a finding of imminent danger to public health or safety. All controlled substance activity stops that day. For a pharmacy, dispensing ends. For a practitioner, prescribing ends. DEA may also place the registrant’s controlled substances under seal.
The standard is statutory and each element is contestable. Imminent danger requires a substantial likelihood of an immediate threat that death, serious bodily harm, or abuse will occur absent immediate suspension, tied to the registrant’s own failure to maintain effective controls or comply with the Controlled Substances Act. Conduct that has stopped, been corrected, or aged is a legitimate target for challenge.
DEA issued 53 Immediate Suspension Orders in the year ending with the June 2026 takedown, against 205 Orders to Show Cause. The agency’s own practice treats immediate suspension as the exception, a point available to a suspended registrant contesting the finding.
What Does Surrendering a DEA Registration During an Investigation Actually Do?
A voluntary surrender for cause ends the registration without any hearing, finding, or review of the government’s evidence. It is typically presented on a DEA form during a field visit, when investigators have assembled their record and the registrant has seen none of it. Reinstatement requires a new application, which DEA evaluates against the same conduct that prompted the surrender.
This is the most common outcome in registrant enforcement. Of the record 928 administrative actions reported for the year ending in June 2026, 642 were surrenders for cause, outnumbering contested Orders to Show Cause by more than three to one.
A surrender also reaches beyond the registration. It is reportable to state licensing boards, payers, hospitals, and credentialing bodies, and it can later be characterized as an acknowledgment of the underlying conduct.
How Does Ruan v. United States Apply, and Does It Govern DEA Administrative Proceedings?
In Ruan v. United States, 597 U.S. 450 (2022), the Supreme Court held that the mens rea in 21 U.S.C. § 841(a)(1) applies to the statute’s authorization clause. The government must prove the practitioner subjectively knew or intended that the prescribing was unauthorized. Objective deviation from prescribing norms, standing alone, does not establish the offense, and an honest belief that prescribing was medically appropriate is a defense.
Ruan does not carry over to the registration case. DEA proceedings under 21 U.S.C. § 824 are remedial rather than punitive and turn on the public interest factors, not criminal intent. A registrant can defeat the criminal charge and still lose the registration on the same conduct.
The clinical record therefore does different work in each forum. In the criminal case it negates subjective knowledge. Before an administrative law judge it answers the public interest factors and supports remediation.
What Is a Corrective Action Plan Under 21 U.S.C. § 824(c) and When Is It Available?
Congress created the corrective action plan in 2016. A registrant served with an Order to Show Cause may submit a plan on or before the hearing date, and DEA must then determine whether to discontinue the proceeding or defer it while the plan is modified or clarified. A credible plan built on documented compliance changes can end a registration case without a hearing.
The right has one significant limit: it does not apply where DEA has issued an Immediate Suspension Order. That distinction largely explains why the difference between an ISO and an Order to Show Cause determines how much of a practice survives the first week.
Deadlines govern the rest. A registrant served with an Order to Show Cause must answer and request a hearing within 30 days, and allegations left unanswered are deemed admitted, permitting revocation by default. Effective plans address the specific findings with dated, verifiable measures rather than general assurances.
What Sentences Are Federal Courts Imposing in 2026 Diversion and Pill Mill Cases?
Sentences remain among the most severe in healthcare enforcement, and they extend well beyond the prescriber. In August 2026, a Texas physician was sentenced to 12.5 years for a clinic that issued prescriptions for more than 3 million opioid pills over roughly three years.
The co-defendants show the range across roles. A nurse practitioner received 96 months. The pharmacist who filled the prescriptions received 42 months. The clinic’s security guard received 63 months. A dealer who brought patients to the clinic and resold the drugs received 210 months.
Platform cases now produce comparable exposure. In July 2026, a telehealth founder was sentenced to six years and fined $1 million, and the company’s clinical president received two years and the same fine, in a scheme involving more than 37 million stimulant pills. Guidelines exposure is driven by drug quantity converted to marijuana equivalency, with enhancements for role, abuse of a position of trust, and death or serious bodily injury.
Can Telehealth Companies and Their Executives Be Prosecuted for Controlled Substances Distribution?
Yes, and the sentences are now on the record. In July 2026, the founder and former CEO of a digital health company was sentenced to six years and fined $1 million, with the clinical president receiving two years and an identical fine. It was DOJ’s first criminal drug distribution prosecution of a telehealth platform, following convictions in November 2025.
The proof targeted platform design rather than individual encounters: capped visit windows, compensation that rewarded prescribing, auto-refills issued without clinical interaction, restrictions on discharging patients after families reported adverse effects, and direction to clinicians to disregard DSM-5 criteria. Marketing aimed at people seeking a specific medication supplied the intent narrative.
Exposure runs to founders, chief executives, medical directors, and prescribing clinicians. The defense focuses on documented clinical oversight, the independence of prescriber judgment, and the separation between growth strategy and prescribing decisions.
What Are the Telemedicine Rules for Prescribing Controlled Substances in 2026?
The Ryan Haight Act, 21 U.S.C. § 829(e), generally requires an in-person medical evaluation before a controlled substance may be prescribed by means of the internet, subject to statutory exceptions.
DEA and HHS published a fourth temporary extension on December 31, 2025, allowing registered practitioners to prescribe Schedule II through V substances by audio-video telemedicine without a prior in-person examination through December 31, 2026. DEA’s final rule on special registrations for telemedicine entered White House review on August 25, 2026, with final action projected for November 2026.
Two points follow. The window between publication of a final rule and expiration of the temporary framework may be short. And the flexibility never changed the substantive standard: a telemedicine prescription must still be issued for a legitimate medical purpose in the usual course of professional practice under 21 C.F.R. § 1306.04. Every 2026 telehealth prosecution was charged under that standard, not under the remote-prescribing rules.
Can a Pharmacist Be Charged for Filling Prescriptions Written by a Licensed Physician?
Yes. A pharmacist has a corresponding responsibility under 21 C.F.R. § 1306.04 to ensure a prescription was issued for a legitimate medical purpose. Filling despite red flags that a prescription lacks one supports criminal liability under 21 U.S.C. § 841, regardless of the prescriber’s license status. The pharmacist who filled prescriptions for the Kingwood pill mill received 42 months in 2026.
The red flags prosecutors cite are consistent: concentrated volume from one prescriber, cash payment, patients traveling long distances, early refills, uniform high-strength quantities, and the opioid, benzodiazepine, and muscle relaxant combination. The government argues the flags were visible in the pharmacy’s own dispensing data.
Pharmacies also face the registration track. An Immediate Suspension Order halts all dispensing the day it is served, and civil penalties under 21 U.S.C. § 842 reach recordkeeping and reporting failures with no diversion allegation at all. The defense documents the verification actually performed: prescriber calls, diagnosis confirmation, monitoring program checks, and refusals to fill.
How Do ARCOS and Prescription Monitoring Data Identify Investigative Targets?
ARCOS records the movement of controlled substances from manufacturers through distributors to dispensing points, and state monitoring programs capture every prescription dispensed to a patient. Together they let investigators see a prescriber’s or pharmacy’s full activity without any complaint being filed.
Investigators screen for deviation from a selected peer group: total volume, concentration in high-strength short-acting formulations, the share of patients on combination therapy, patient travel distance, and the concentration of a pharmacy’s volume from a single prescriber. Part D and Medicaid claims add the payment layer.
These models are contestable. Peer groups are built on specialty codes that often fail to capture a practice, and a physician who accepts referrals other clinicians decline will appear as an outlier for that reason. The defense tests the comparison group, date range, exclusions, and arithmetic behind the government’s charts.
Does a Controlled Substances Case End a Medical or Pharmacy Career?
Consequences frequently arrive before any conviction. An Immediate Suspension Order ends prescribing or dispensing on the day of service, and a Medicare payment suspension can stop revenue on a credible allegation of fraud. State boards commonly act on an indictment rather than waiting for a verdict, and hospitals, payers, and credentialing bodies follow.
A conviction for a program-related offense triggers mandatory exclusion from federal healthcare programs for a minimum of five years, and a controlled substance felony conviction is an independent ground for revocation under 21 U.S.C. § 824.
Not every outcome is terminal. Registration cases resolved through corrective action plans or memoranda of agreement permit continued practice under monitoring, and civil resolutions under 21 U.S.C. § 842 routinely leave registrations intact. Which path a matter takes is often determined in the first weeks, before anything is filed.
Why Does Federal Trial Experience Matter in a Diversion or Pill Mill Defense?
Because the government tries these cases and wins them. DOJ’s Healthcare Fraud Unit completed nine jury trials through early June 2026, all resulting in convictions, after 17 trials in 2025, and assigns trial-designated prosecutors paired with data analysts.
Trial capability also determines the quality of the pretrial record. Counsel preparing for a jury retains clinical experts early, litigates the admissibility and construction of the prescribing summaries, develops impeachment on cooperating witnesses, and preserves the Ruan instruction issues that matter on appeal.
Armstrong & Bradylyons PLLC brings 25 federal jury trials in complex fraud cases, including 17 healthcare fraud trials at DOJ involving more than $2.8 billion in alleged false claims. Scott Armstrong directed DOJ’s ARPO Strike Force across 10 federal districts in six states and served as lead trial counsel in the Fraud Section’s first data-analytics prescribing prosecution, a two-week jury trial of a physician and clinic owner for conspiring to unlawfully dispense over 2 million opioid pills.